Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion. Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 Å...

Detaylı Bibliyografya
Asıl Yazarlar:	Kim, H, Tan, L, Weisberg, E, Liu, F, Canning, P, Choi, H, Ezell, SA, Wu, H, Zhao, Z, Wang, J, Mandinova, A, Griffin, J, Bullock, A, Liu, Q, Lee, S, Gray, N
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2013

Benzer Materyaller

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
Yazar:: Kim, H, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors
Yazar:: Canning, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Yazar:: Canning, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
Yazar:: Maria G. Nava, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
Yazar:: López-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
Yazar:: López-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation
Yazar:: William A. Denny, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
Yazar:: Panupong Mahalapbutr, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
Yazar:: Ronnakorn Leechaisit, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Yazar:: Patrice Dubreuil, ve diğerleri
Baskı/Yayın Bilgisi: (2009-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
Yazar:: Xu H, ve diğerleri
Baskı/Yayın Bilgisi: (2019-07-01)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
Yazar:: Sudarshan R Iyer, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Recent Advances in Discovery of New Tyrosine Kinase Inhibitors Using Computational Methods
Yazar:: Vesna Rastija
Baskı/Yayın Bilgisi: (2019-08-01)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
Yazar:: Chunmin Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
Yazar:: Hellwig, S, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
Yazar:: Lopez-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Kindlin-3 inactivation mediates melanoma agressiveness through crosstalk with the collagen-activated tyrosine kinase receptor DDR1
Yazar:: C. Reger de Moura, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Yazar:: Ellen Weisberg, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
Yazar:: Ian M. Catlett, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
Yazar:: Maria Dimou, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
Yazar:: Elisabetta Abruzzese, ve diğerleri
Baskı/Yayın Bilgisi: (2014-04-01)

Second-generation inhibitors of Bruton tyrosine kinase
Yazar:: Jingjing Wu, ve diğerleri
Baskı/Yayın Bilgisi: (2016-09-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
Yazar:: Cornelius Hempel, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents
Yazar:: Yangyang Yao, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
Yazar:: John J. Ryan, MD
Baskı/Yayın Bilgisi: (2016-12-01)

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Yazar:: Zhao, Z, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
Yazar:: Ainun Nizar Masbuchin, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
Yazar:: G. V. Lukina, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Yazar:: Huang JT, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Yazar:: Mark C Weir, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
Yazar:: Tatsuki Shibuta, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
Yazar:: Chris Liang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
Yazar:: Jiangnan Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
Yazar:: Wu J, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Integrating machine learning and structure-based approaches for repurposing potent tyrosine protein kinase Src inhibitors to treat inflammatory disorders
Yazar:: Muhammad Waleed Iqbal, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
Yazar:: Pitsiou G, ve diğerleri
Baskı/Yayın Bilgisi: (2014-10-01)

509 Potent and selective inhibition Of AXL receptor tyrosine kinase for the treatment of cancer
Yazar:: Matthew Walters, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma
Yazar:: Wei Dai, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors
Yazar:: Bullock, A, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
Yazar:: Evan Pisick, ve diğerleri
Baskı/Yayın Bilgisi: (2004-01-01)